In this context, both non-pharmacological anti-inflammatory strategies such as exercise [18] and pharmacological ones such as β2-AR agonists [31,32] aimed at regulating the inflammatory activity of macrophages in obesity and diabetic complications, should avoid, if optimal, a potential immunocompromised status of obese individuals against pathogen challenge, particularly when exercise and pharmacological strategies are combined [9,19]. The gene discussed is ADRB2; the disease is obesity disorder.